Tagged with Immuno Cure

China: Sciwind Confirms Obesity Ambitions with Positive Phase III Readout; FDA Blocks Cell Exports to China

China China: Sciwind Confirms Obesity Ambitions with Positive Phase III Readout; FDA Blocks Cell Exports to China

China A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled research deal with CSPC Pharmaceuticals, and the FDA blocks clinical trials that export American’s cells to China. Sciwind’s GLP‑1 data…

Clinical Trial Diversification: What do Hong Kong & the Greater Bay Area Have to Offer?

Hong Kong Clinical Trial Diversification: What do Hong Kong & the Greater Bay Area Have to Offer?

Hong Kong Hong Kong has grand plans to become one of Asia’s leading clinical trial hubs. Important regulatory upgrades and increased integration with mainland China via the Greater Bay Area initiative – including a new dedicated GBA Clinical Trial Institute at the Hong Kong/mainland border – mean that this is not just…

Xia JIN – CEO & Tom LAU – Director of Corporate Finance, Immuno Cure

Hong Kong Xia JIN – CEO & Tom LAU – Director of Corporate Finance, Immuno Cure

Hong Kong Immuno Cure has a unique approach to the failure-ridden field of HIV vaccine development: focusing on a therapeutic vaccine for already infected individuals rather than a preventive vaccine. Founders Tom Lau and Dr Xia Jin explain the company’s origins as a spin-off from the University of Hong Kong’s AIDS Institute…